Skip to main content

Table 1 Correlation between clinicopathological features and each intrinsic subtype in 237 patients treated with NAC

From: Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy

Parameters Intrinsic subtype p-value
Luminal
(n = 93)
Luminal-HER2
(n = 21)
HER2-enriched
(n = 43)
TNBC
(n = 80)
Age at operation
 ≤ 56 48 (51.6%) 12 (57.1%) 18 (41.9%) 39 (48.8%)  
 > 56 45 (48.4%) 9 (42.9%) 25 (58.1%) 41 (51.2%) 0.641
Menopause
 Pre- 42 (45.1%) 9 (42.9%) 15 (34.9%) 29 (36.3%)  
 Post- 51 (54.9%) 12 (57.1%) 28 (65.1%) 51 (63.7%) 0.564
Tumor size (cm)
 ≤ 2 13 (14.0%) 5 (23.8%) 5 (11.6%) 9 (11.3%)  
 > 2 80 (86.0%) 16 (76.2%) 38 (88.4%) 71 (88.7%) 0.546
Lymph node status
 Negative 20 (21.5%) 9 (42.9%) 14 (32.6%) 22 (27.5%)  
 Positive 73 (78.5%) 12 (57.1%) 29 (67.4%) 58 (72.5%) 0.206
Nuclear grade
 1, 2 76 (81.7%) 18 (85.7%) 35 (81.4%) 65 (81.3%)  
 3 17 (18.3%) 3 (14.3%) 8 (18.6%) 15 (18.7%) 0.969
Ki67 (%)
 ≤ 14 34 (36.6%) 11 (52.4%) 15 (34.9%) 19 (23.8%)  
 > 14 59 (63.4%) 10 (47.6%) 28 (65.1%) 61 (76.2%) 0.066
Pathological response
 Non-pCR 70 (73.8%) 15 (71.4%) 19 (44.2%) 42 (52.5%)  
 pCR 23 (26.2%) 6 (28.6%) 24 (55.8%) 38 (47.5%) 0.001
  1. NAC neoadjuvant chemotherapy, HER2 human epidermal growth factor receptor 2, TNBC triple-negative breast cancer, pCR pathological complete response